Anemia management in patients with chronic renal insufficiency.
The introduction of recombinant human erythropoietin (rHuEPO) more than a decade ago provided the first effective treatment for the anemia of chronic renal insufficiency (CRI). The use of rHuEPO in the treatment of anemia has been associated with partial regression of left ventricular hypertrophy among both dialysis and nondialysis patients, and has been shown to reduce the frequency of cardiac complications such as congestive heart failure and number of days of hospitalization among dialysis patients. Despite this evidence, the anemia of CRI remains highly prevalent, underrecognized, and undertreated. A number of considerations arise regarding the management of anemia among patients with CRI. In this article, we review the rationale for treatment of anemia, current management practices, proposed treatment strategies, and the economic implications of improved anemia treatment.
Kausz
A T
AT
Division of Nephrology, Department of Medicine, New England Medical Center, Boston, MA 02111, USA.
Obrador
G T
GT
Pereira
B J
BJ
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology; D004921:Erythropoietin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D011994:Recombinant Proteins; D012307:Risk Factors
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin